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The systolic^diastolic difference in carotid stiffness is
increased in type 2 diabetes:TheMaastricht Study
Marja G.J. Veugena,b, Ronald M.A. Henrya,b,c, Thomas T. van Slotena,b, Evelien Hermelingd,
Hans-Peter Brunner-La Roccae, Miranda T. Schrama,b,c, Pieter C. Dagnelieb,f,g,
Casper G. Schalkwijka,b, Abraham A. Kroona,b, Coen D.A. Stehouwera,b, and Koen D. Reesinkb,h
Objective: In type 2 diabetes (T2D), increased arterial
stiffening results from accelerated arterial wall matrix
remodeling. The associated structural alterations modify
the pressure dependency of arterial stiffness, which can be
quantified by the systolic–diastolic difference in carotid
pulse wave velocity (dPWV). We evaluated the association
between T2D and dPWV as marker for matrix remodeling
and whether dPWV may contain additional information
beyond carotid stiffness (cPWV).
Methods: In 746 individuals from The Maastricht Study,
415 with normal glucose metabolism; 126 with
prediabetes; and 205 with T2D, carotid pulse wave velocity
(cPWV) and dPWV were determined by ultrasonography
and tonometry. Multiple linear regression analyses were
used to investigate associations of glucose metabolism
status (with normal glucose metabolism as reference) with
cPWV and dPWV, adjusting for age, sex, mean arterial
pressure, prior cardiovascular disease, estimated glomerular
filtration rate and smoking, and dPWV or cPWV as
appropriate.
Results: After adjustment for age, sex, mean arterial
pressure, prior cardiovascular disease, estimated glomerular
filtration rate and smoking, T2D was associated with
greater cPWV [b (95% confidence interval) 0.376 (0.119;
0.632)] and dPWV [0.301 (0.013; 0.589)]. After additional
adjustment for dPWV or cPWV, associations of T2D with
cPWV and dPWV were attenuated [0.294 (0.048; 0.539)
and 0.173 (0.103; 0.449), respectively]. Prediabetes was
not associated with either cPWV or dPWV.
Conclusion: The systolic-diastolic difference in carotid
stiffness is increased in T2D, but not prediabetes.
Importantly, the association was not abolished by carotid
stiffness, which suggests that systolic–diastolic difference
in carotid stiffness carries additional information regarding
arterial matrix remodeling.
Keywords: arterial stiffness, collagen crosslinking, elastin
degradation, pulse wave velocity, vascular remodeling
Abbreviations: r, blood density; dPWV, systolic–diastolic
difference in carotid pulse wave velocity; AGE, advanced
glycation endproduct; CEL, Ne-(carboxyethyl)lysine; cfPWV,
carotid-to-femoral pulse wave velocity; CML, Ne-
(carboxymethyl)lysine; cPWV, carotid pulse wave velocity;
CVD, cardiovascular disease; D, diameter; DC, distensibility
coefficient; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; HOMA2-IR, homeostasis model
assessment 2 for insulin resistance; HR, heart rate; IMT,
intima–media thickness; MAP, mean arterial pressure;
NGM, normal glucose metabolism; PPcar, local carotid
pulse pressure; RAS-inhibitor, renin–angiotensin system
inhibitor; SAF, skin autofluorescence; SBP, systolic blood
pressure; T2D, type 2 diabetes; DD, distension
INTRODUCTION
A
rterial stiffening underlies increased cardiovascular
disease (CVD) and cardiovascular risk [1,2], and is
the result of structural alterations in the arterial wall
matrix. Arterial matrix remodeling affects the arterial pres-
sure–area relationship [3–5]. The pressure–area relation-
ship defines the change in arterial cross-sectional area in
response to changes in transmural pressure. The slope of
the pressure–area relationship is directly related to the
vessel’s stiffness. From the slope, one can derive a corre-
sponding pulse wave velocity, which is the measure used to
quantify stiffness. The systolic–diastolic difference in car-
otid pulse wave velocity (dPWV), as obtained from carotid
artery measurements, is a property of the pressure–area
relationship, that is, it quantifies the pressure dependency
of arterial stiffness (Fig. 1a) [6]. Greater dPWV is associated
with left ventricular mass index, independent of existing
arterial stiffness measures [6]. It has not been established
whether dPWV may add to our understanding of arterial
matrix remodeling. Therefore, the goal of the current study
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was to evaluate dPWV as a marker of arterial matrix remod-
eling.
In type 2 diabetes (T2D), arterial matrix remodeling is
increased or ‘accelerated’ [7]. The elastin and collagen fiber
network in T2D may be damaged due to cyclic or metabolic
stress, leading to increased arterial stiffness via increased
elastin degradation [8–10] and increased collagen cross-
linking [10–15]. Given the accelerated elastin and collagen
remodeling in T2D, we hypothesized that dPWV is greater
in T2D (Fig. 1b).
Therefore, we investigated in a well characterized popu-
lation-based cohort the association between glucose
metabolism status [i.e. normal glucose metabolism
(NGM), prediabetes and T2D] and dPWV. In our analysis,
we considered whether or not dPWV contains information
beyond carotid stiffness, as derived from distensibility and
expressed as carotid pulse wave velocity (cPWV).
METHODS
Study population
We used data from The Maastricht Study, an observational
prospective population-based cohort study. The rationale
and methodology have been described previously [16]. In
brief, the study focuses on the etiology, pathophysiology,
complications and comorbidities of T2D and is character-
ized by an extensive phenotyping approach. Eligible for
participation were all individuals aged between 40 and
75 years and living in the southern part of The Netherlands.
Participants were recruited through mass media campaigns
and from the municipal registries and the regional Diabetes
Patient Registry via mailings. Recruitment was stratified
according to known T2D status for reasons of efficiency.
The present report includes cross-sectional data from the
first 866 participants who completed the baseline survey
between November 2010 and March 2012. The examin-
ations of each participant were performed within a time
window of 3 months. The study has been approved by the
institutional medical ethical committee (NL31329.068.10)
and the Minister of Health, Welfare and Sports of The
Netherlands (Permit 131088-105234-PG). All participants
gave written informed consent.
Arterial measurements
Carotid and aortic arterial stiffness, and dPWV, were
assessed noninvasively by means of vascular ultrasound
and applanation tonometry. All measurements (approxi-
mately 45min) were done by trained vascular technicians
unaware of the participants’ clinical or diabetes status.
Measurements took place in a quiet temperature-controlled
room (21–23 8C) and were performed in supine position,
after 10min of rest. Participants were asked to refrain from
smoking and drinking coffee or tea or alcohol beverages 3 h
prior to the study. Participants were allowed to have a light
meal (breakfast and/or lunch). Talking or sleeping was not
allowed during the examination. A three-lead ECG was
recorded continuously during the measurements to facili-
tate automatic signal processing. In addition, during the
vascular assessment, brachial systolic, diastolic and mean
arterial pressure (MAP) were determined repeatedly with a
5-min interval, using an oscillometric device (Accutorr Plus;
Datascope Inc.; Montvale, New Jersey, USA), and the aver-
age of these measurements was calculated and used in the
statistical analyses.
Arterial tonometry
Tonometric waveforms were determined at the right com-
mon carotid and right common femoral arteries (Sphygmo-
cor; Sydney, Australia). The difference in the time of pulse
arrival from the R-wave of the ECG between the two sites
(transit time) was determined by an intersecting tangent
algorithm. The pulse wave travel distance was calculated as
80% of the direct straight distance (measured with an
infantometer) between the two arterial sites. The median
of three consecutive carotid-to-femoral pulse wave velocity
(cfPWV, defined as traveled distance/transit time) record-
ings was used in the analyses.
Carotid artery ultrasound measurements
The left common carotid artery (at least 10mm proximal to
the carotid bulb) was obtained by using a 7.5-MHz linear
probe of an ultrasound scanner (MyLab70; Esaote Europe
B.V.; Maastricht, The Netherlands). This setup enables the
measurement of diameter (D), distension (DD) and intima–
media thickness (IMT) as described elsewhere [17,18].
During the ultrasound measurements, a B-mode image
on the basis of 19 M-lines was depicted on screen, and
an online echo-tracking algorithm showed real-time
anterior and posterior arterial wall displacements. The
P
re
ss
ur
e
Cross-sectional area
(a) (i) (ii)
(b)
Cross-sectional area
Increasing cross-linking
in collagen network
Structural degradation
of elastin network
SBP
DBP
Increased
δPWV
P
re
ss
ur
e
Cross-sectional area
δPWV ≈ 0
P
re
ss
ur
e
δPWV > 0
Increased
δPWV
FIGURE 1 (a) (i) The systolic–diastolic difference in carotid pulse wave velocity
(dPWV) in a linear pressure–area curve is more or less equal to 0, i.e. negligible
pressure dependency of arterial stiffness. (ii) dPWV in a curvilinear pressure–area
curve is greater than zero, signifying pressure dependency of arterial stiffness
(refer to [6]). Note that in both cases, carotid pulse wave velocity is equal, as
signified by the shaded areas. (b) dPWV as a marker of arterial matrix remodeling
known to occur in type 2 diabetes. Greater dPWV is reflected by progressive
degradation of the elastin network, leading to an increase in cross-sectional area,
whether or not in combination with stiffening of the collagen network leading to
a progressively steeper pressure–area curve. The effect of elastin degradation is
indicated with a blue dotted line and the effect of increased collagen crosslinking
with a red dotted line.
Systolic–diastolic difference in carotid stiffness
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M-mode recordings were composed of 19 simultaneous
recordings at a frame rate of 498 Hz. The distance between
the M-line recording positions was 0.96 mm; thus, a total
segment of 18.24 mm of each artery was covered by the
scan plane. For offline processing, the radiofrequency
signal was fed into a dedicated PC-based acquisition system
(ART.LAB; Esaote Europe B.V.) with a sampling frequency
of 50MHz. Data processing was performed in MATLAB
(version 7.5; MathWorks; Natick, Massachusetts, USA).
The distension waveforms were obtained from the radio-
frequency data with the use of a wall track algorithm [17].
Carotid IMT was defined as the distance of the posterior
wall from the leading edge interface between lumen and
intima to the leading edge interface between media and
adventitia [18]. The median diameter, distension and IMT of
three measurements were used in the analyses.
Local carotid pressure calibration
Pulse pressure at the carotid artery (PPcar) was calculated by
calibrating the systolic–diastolic amplitude of the carotid
artery tonometry waveform (sys-dias)tono to pressure,
assuming a constant difference between MAP and diastolic
blood pressure (DBP) along the large arteries: PPcar¼ (sys-
dias)tono (MAPDBP)brach/(mean-dias)tono.
This procedure was the same as those described by Kelly
and Fitchett [19] and Van Bortel et al. [20], except that the
MAP and DBP values at the brachial artery were taken as the
respective averages over the vascular measurements (i.e.
over a 30–45min period) as obtained with a validated
commercial oscillometric device (Accutorr Plus; Datascope
Inc.). Cited procedures considered the mean–diastolic
difference as obtained from a measured brachial artery
pressure or diameter waveform.
Calculation of carotid pulse wave velocity and
systolic–diastolic difference in carotid pulse wave
velocity
Carotid artery stiffness was expressed in terms of cPWV (in
units of m/s) based on the Bramwell–Hill relation [21]:
cPWV ¼ 1
sqrt rDCð Þ ;
with DC, the carotid distensibility coefficient calculated
from the ultrasonography and tonometry derived
parameters as defined below [22].
DC ¼ 2DD Dþ DD
2ð Þ
PPcar  D2ð Þ
;
with PPcar, the local carotid PP (calibration described above).
Accordingly, we obtained a systolic and diastolic PWV
based on systolic, diastolic and dicrotic notch pressure and
diameter values. dPWV was then calculated by subtracting
the diastolic from the systolic PWV, as described in further
detail by Hermeling et al. [6].
Reproducibility
Reproducibility was assessed in 12 individuals (six men;
60.8 6.8 years; six with T2D) who were examined by two
observers at two occasions spaced 1 week apart. The
intraobserver and interobserver intraclass correlation coef-
ficients were 0.87 and 0.69 for cfPWV and 0.85 and 0.73 for
the carotid distensibility coefficient.
Glucose metabolism status and other covariates
Glucose metabolism status was assessed as described pre-
viously [16,23]. For the current study, impaired fasting
glucose and impaired glucose tolerance were combined
into prediabetes. T2D consisted of newly diagnosed and
known T2D. Newly diagnosed T2D was defined as having
T2D according to the WHO 2006 criteria [23] and no self-
reported T2D. Medical history, prior CVD, medication use
(glucose-lowering, antihypertensive and lipid-modifying),
smoking status (never, former and current), BMI, waist and
hip circumference, total cholesterol, HDL cholesterol,
LDL cholesterol, triglycerides, glycosylated hemoglobin
(HbA1c) and fasting glucose levels were assessed as
described previously [16]. Insulin was quantified on a Meso
Scale custom duplex assay (Meso Scale Discovery; Gaithers-
burg, Maryland, USA). Detection ranges of the assay were
35–25 000 pg/ml, and the interassay coefficient of variation
was 10.1%. Insulin was converted from pg/ml to pmol/l
using a molar mass of 5808 g. Insulin resistance was
estimated from fasting insulin and glucose by the Homeo-
stasis Model Assessment 2 for Insulin Resistance (HOMA2-
IR) and calculated using the HOMA2 calculator (version
2.2.3. for Windows; available from https://www.dtu.ox.a-
c.uk/homacalculator). Prior CVD was defined as a history of
myocardial infarction, cerebrovascular infarction or hem-
orrhage and(or) vascular surgery (including percutaneous
angioplasty) of the coronary arteries, abdominal arteries,
peripheral arteries or carotid arteries. Waist-to-hip ratio was
calculated by dividing waist circumference by hip circum-
ference. Total-to-HDL cholesterol ratio was calculated by
dividing total cholesterol by HDL cholesterol.
Serum creatinine and serum cystatin C to estimate the
glomerular filtration rate (eGFR) according to the Chronic
Kidney Disease Epidemiology Collaboration equation [24]
were measured as described previously [25]. Twenty-
four-hour urinary albumin excretion was assessed as
described previously, based on one or preferably two urine
collections extrapolated to 24 h [25]. The presence of
microalbuminuria or macroalbuminuria (urinary albumin
excretion of 30–300 mg or urinary albumin excretion of
more than 300 mg per 24 h, respectively [26]) was dicho-
tomized.
MAP determined during vascular assessment was used as
a primary covariate in linear regression analyses. Office and
ambulatory blood pressures (BPs) were measured as
described previously [15,16]. Mean 24-h systolic BP (SBP)
and DBP were calculated based on hourly averages [27] and
were only calculated if there were more than 14 valid
measurements during daytime and more than seven valid
measurements at night [28]. Twelve individuals were
excluded because of invalid measurements at night. The
remaining missing data on 24-h ambulatory BP monitoring
were caused by device nonavailability or technical prob-
lems. Hypertension was defined as an office, and in a
separate definition also 24-h, SBP  140 mmHg, an office
or 24-h DBP  90 mmHg and(or) the use of antihyperten-
sive medication [16,27].
Veugen et al.
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Advanced glycation endproducts (AGEs) were measured
as skin autofluorescence (SAF) using the AGE reader (Diag-
nOptics Technologies BV, Groningen, The Netherlands)
and by means of plasma AGEs using HPLC with fluor-
escence detection for protein-bound pentosidine and ultra-
performance liquid chromatography tandem mass
spectrometry for protein-bound Ne-(carboxymethyl)lysine
(CML) and Ne-(carboxyethyl)lysine (CEL), as described
previously [12].
Statistical analysis
All statistical analyses were performed using SPSS version
21 (IBM SPSS, IBM Corp; Armonk, New York, USA). A two-
sided P value of 0.05 was considered statistically significant.
Differences in population characteristics between NGM,
prediabetes and T2D were tested by ANOVA for continuous
variables normally distributed, log transformed if necessary,
and with chi-square test for dichotomous or categorical
variables.
Associations of glucose metabolism status with cPWV
and dPWV were investigated with multivariable linear
regression analyses with NGM as reference category. The
analyses were executed crude (model 1) and additionally
adjusted for sex, age and MAP (model 2); prior CVD, eGFR
and smoking (model 3); and the use of renin–angiotensin
system inhibitors (RAS-inhibitors) [29] (model 4). Finally,
we additionally adjusted the association between glucose
metabolism status and dPWV for cPWV and vice versa to
investigate whether the associations of glucose metabolism
status with dPWV and cPWV were independent of each
other (model 5).
RESULTS
Study population
From the initial 866 individuals, we excluded four individ-
uals with type 1 diabetes. In the remaining 862 individuals,
pulse wave analysis data were available in 808 participants.
The reason for the missing pulse wave analysis data was
either for logistical reasons or technical failure. From those
808 individuals, a further 12 were excluded with a dPWV
less than 0m/s due to measurement errors. An additional 50
individuals were excluded because they had missing values
on prior CVD, eGFR or smoking (not mutually exclusive).
The current study population therefore consisted of 746
individuals (415 individuals with NGM, 126 individuals with
prediabetes and 205 with T2D of whom 32 were newly
diagnosed T2D).
The missing or excluded individuals more often had
T2D, more often suffered from hypertension, had lower
eGFR, greater BMI and cfPWV. In addition, they more often
used lipid-modifying medication and lower total and LDL
cholesterol levels.
Clinical characteristics of the study population
Table 1 shows the characteristics of the study population
according to glucose metabolism status. Individuals with
T2D were on average older, were more often men, and had
a greater BMI as compared with individuals with NGM
and(or) prediabetes. In addition, individuals with T2D
suffered more often from hypertension and CVD.
Individuals with T2D had a greater carotid diameter as
well as greater IMT. In addition, individuals with T2D had a
higher PPcar (Table 1).
Both cPWV and dPWV were higher in individuals with
T2D as compared with individuals with NGM and(or)
prediabetes (Table 1).
Association of glucose metabolism status with
carotid pulse wave velocity and systolic–
diastolic difference in carotid pulse wave
velocity
Table 2 shows the associations of T2D with cPWV and
dPWV as compared with NGM. After adjustment for sex, age
and MAP (covariates of model 2), T2D was associated with
greater cPWV and dPWV: regression coefficient b (95%
confidence interval): 0.377 (0.124; 0.629) and 0.311
(0.027; 0.595), respectively (model 2; Table 2). Further
adjustment for prior CVD, eGFR and smoking (model 3;
Table 2) did not materially change the results: 0.376 (0.119;
0.632) and 0.301 (0.013; 0.589), respectively. If we then
further adjusted these associations for the use of RAS-
inhibitor, the results did not materially alter: 0.322 (0.051;
0.594) and 0.331 (0.026; 0.636), respectively (model 4;
Table 2).
Prediabetes was not associated with cPWV or dPWV after
adjustment for any of the variables of the models 2, 3 and 4
(Supplemental Table S2, http://links.lww.com/HJH/A741).
Mutual adjustments for carotid pulse wave
velocity and systolic–diastolic difference in
carotid pulse wave velocity
If we additionally adjusted the association between T2D
and cPWV for dPWV, the results showed that the association
between T2D and cPWV attenuated from 0.376 (0.119;
0.632) to 0.294 (0.048; 0.539) (model 5; Table 2).
If we additionally adjusted the association between
glucose metabolism status and dPWV for cPWV; the results
showed that the association between T2D and dPWV atte-
nuated from 0.301 (0.013; 0.589) to 0.173 (0.103; 0.449)
(model 5; Table 2).
Additional analyses
The results were not materially altered if we additionally
adjusted the association of T2D with cPWV and dPWV for
cfPWV (Supplemental Table S1, http://links.lww.com/
HJH/A741). In addition, the results were not materially
altered if we additionally adjusted the association for
SAF, plasma AGEs, insulin or HOMA2-IR (Supplemental
Table S3b, http://links.lww.com/HJH/A741). The results
did however attenuate if we additionally adjusted the
association of T2D with cPWV and dPWV for HbA1c
(Supplemental Table S3b, http://links.lww.com/HJH/
A741).
The results between T2D and cPWV were not materially
altered if we additionally adjusted model 3 for either
hypertension based upon office or ambulatory BPs and(or)
the use of antihypertensive medication or specifically the
use of beta-blockers. In a series of exploratory analyses, the
results were also not materially altered if we additionally
adjusted model 3 for heart rate (HR) at time of vascular
Systolic–diastolic difference in carotid stiffness
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measurement, BMI, waist circumference or waist–hip ratio,
lipid profile, the use of lipid-modifying medication or the
presence of albuminuria (Supplemental Table S1, http://
links.lww.com/HJH/A741).
The results between T2D and dPWV were not materially
altered if we additionally adjusted model 3 for hyperten-
sion based upon ambulatory BPs and(or) the use of anti-
hypertensive medication or the presence of albuminuria.
In a series of exploratory analyses, the results were
materially altered if we additionally adjusted model 3 for
hypertension based upon office BPs and the use of anti-
hypertensive medication, BMI or waist circumference or
waist-to-hip ratio, lipid profile and the use of lipid-
modifying medication, or HR at time of vascular measure-
ment. Overall, the associations attenuated, except for HR in
which the association between T2D and dPWV became
stronger (Supplemental Table S1, http://links.lww.com/
HJH/A741).
TABLE 1. General characteristics of the study population according to glucose metabolism status
Total study
population
Normal glucose
metabolism (n¼415)
Prediabetes
(n¼126)
Type 2 diabetes
(n¼205) P-value
Demographics
Men, n (%) 416 (56) 194 (47) 75 (60) 147 (72) <0.001
Age (years) 608 578 627 637 <0.001
Blood pressure
24-h systolic blood pressure (mmHg)b 11912 11711 12213 12413 <0.001
24-h diastolic blood pressure (mmHg)b 747 747 758 747 0.870
Hypertension (%)c 57 40 66 86 <0.001
Hypertension 24 h (%)d 44 25 55 74 <0.001
Anti-hypertensive medication (%) 38 21 43 71 <0.001
RAS-inhibitors (%) 29 14 33 57 <0.001
ACE-inhibitors (%) 12 6 10 25 <0.001
Angiotensin II inhibitors (%) 17 9 22 31 <0.001
Renin inhibitors (%) <1 0 0 1 0.267
Beta-blockers (%) 17 8 21 35 <0.001
Metabolic variables
BMI (kg/m2) 27.24.4 25.73.7 28.14.0 29.64.6 <0.001
Waist-to-hip-ratioa 0.950.09 0.910.08 0.960.08 1.010.08 <0.001
Total cholesterol (mmol/l)e 5.251.20 5.531.09 5.561.17 4.481.09 <0.001
High-density lipoprotein cholesterol (mmol/l)f 1.320.43 1.430.41 1.310.37 1.120.42 <0.001
Low-density lipoprotein cholesterol (mmol/l)g 3.311.04 3.590.92 3.541.01 2.600.96 <0.001
Triglycerides (mmol/l)f 1.20 (0.86; 1.75) 1.02 (0.74; 1.46) 1.41 (1.01; 2.07) 1.63 (1.15; 2.29) <0.001
Lipid-modifying medication (%) 35 15 36 75 <0.001
HbA1c (%)h 6.00.8 5.60.3 5.90.4 6.90.9 <0.001
FPG (mmol/l)i 6.11.5 5.20.4 6.00.6 7.81.8 <0.001
Glucose-lowering medication
None (%) – 100 100 22
Oral glucose-lowering medication (%)
Insulin use (%) – – – 5
Oral glucose-lowering medication and insulin use (%) – – – 14
Other cardiovascular risk factors
Prior cardiovascular disease (%) 18 12 18 29 <0.001
Smoking status: never/former/current (%) 31.1/52.5/16.4 36.9/45.8/17.3 27.8/57.1/15.1 21.5/63.4/15.1 <0.001
eGFR (ml/min per 1.73m2) 88.314.6 90.913.7 85.314.2 85.015.6 <0.001
Albuminuria (%)j 7 3 6 16 <0.001
Vascular measurements
Carotid diameter (mm) 7.830.85 7.640.82 8.000.88 8.110.79 <0.001
Intima–media thickness (mm) 0.850.15 0.820.13 0.880.18 0.890.15 <0.001
cPWV (m/s) 8.51.8 8.11.7 8.81.8 9.11.9 <0.001
dPWV (m/s) 3.91.9 3.61.8 4.01.7 4.42.0 <0.001
cfPWV (m/s)k 8.92.1 8.31.7 9.32.0 9.82.3 <0.001
Mean arterial pressure (mmHg) 9810 9610 10010 999 0.002
Systolic blood pressure(mmHg)l 12914 12614 13214 13214 <0.001
Diastolic blood pressure (mmHg)m 778 768 787 777 0.742
Heart rate (beats/min)m 639 628 639 6610 <0.001
Brachial pulse pressure (mmHg)n 5210 499 5410 5511 <0.001
Carotid pulse pressure (mmHg) 5114 4813 5414 5615 <0.001
N¼746. Data are presented as mean SD, median (interquartile-range) or frequencies (in %) as appropriate. Linear trend across glucose metabolism status was tested by ANOVA for
continuous variables normally distributed, log transformed if necessary. For dichotome variables a chi-square test was used.
ACE, angiotensin-converting-enzyme; BMI, body mass index; cPWV, local carotid pulse wave velocity; cfPWV, carotid-to-femoral pulse wave velocity; dPWV, systolic-diastolic difference
in carotid pulse wave velocity; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin.
Numbers for specific variables for the total study population, and according to glucose metabolism status are awaist-to-hip-ratio 742, 412/126/204; b24-h blood pressure measurements
668, 374/112/182; chypertension 745, 414/126/205; dhypertension 24 h 704, 381/120/203; etotal cholesterol 743, 414/125/204; fhigh-density lipoprotein cholesterol, triglycerides 743,
413/125/205; glow-density lipoprotein cholesterol 739, 411/125/203; hHb1Ac 742, 412/125/205; iFPG 744, 414/126/204; jpresence of albuminuria 736, 411/125/200; kcfPWV 735, 411/
124/200; lmean SBP 744, 414/126/205; mmean DBP and mean HR 745, 415/126/204; nbrachial PP 744, 414/126/204.
None in type 2 diabetes consisted of 32 patients with newly diagnosed type 2 diabetes and 13 on which no further information was available.
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DISCUSSION
To the best of our knowledge, the present population-
based study is the first to investigate the association
between glucose metabolism status and dPWV. We found
that T2D, but not prediabetes, was associated with greater
dPWV, independent of age, sex, MAP, prior CVD, eGFR and
smoking. The association of T2D with dPWV was not
abolished by carotid stiffness, which suggests that dPWV
contains additional information regarding arterial matrix
remodeling, that is beyond carotid stiffness.
Biomechanically, dPWV reflects the degree to which
stiffness at lower arterial pressure or distension increases
toward greater stiffness at higher pressure or distension.
This intrinsic pressure-dependent behavior is caused by the
properties and configuration of the elastin collagen matrix
(Fig. 1b). In the current study, we utilized T2D as a setting
with known increased arterial matrix remodeling to assess
the potential of dPWV therein. This increased matrix
remodeling in T2D may be the result of increased cyclic
and/or metabolic stress due to increased elastin degra-
dation [8–10] and increased collagen crosslinking [10–
15,30]. The evidence for the contribution of elastin degra-
dation to increased dPWV in T2D, as supported by studies
in the context of vascular aging [8,9,31], appears more
indirect. It is found that in the arterial media of stiffer
arteries, focal calcifications are colocalized with fragmented
elastin [10,32]. However, it remains to be established
whether the calcium crystals are responsible for increased
stiffness or that the coincident elastin degradation causes
the increased stiffness. Nonetheless, the higher prevalence
of calcified peripheral arteries in T2D [33] may reflect
increased elastin degradation in T2D. With regard to
increased collagen crosslinking, it has been hypothesized
that this is particularly driven by the formation of AGEs in
T2D [10,12,13,15,34,35]. In our study however, further
adjustment for SAF or the plasma AGEs – pentosidine,
CML and CEL – did not materially alter our results. This
could potentially be explained by the fact that SAF and
plasma AGEs might not adequately represent AGEs at tissue
level of the arterial wall itself [36] and thus may not
adequately represent any underlying remodeling proc-
esses. Furthermore, it has been shown that AGEs do not
necessarily behave similar with deteriorating glucose
metabolism status [37] to such an extent that it has been
shown that plasma AGEs were associated with left ventric-
ular dysfunction in NGM, but not in T2D. Finally, AGEs do
not solely determine matrix remodeling on their own, and
other mechanisms (e.g. altered matrix metalloproteinase
function) might be operative [38–40]. Interestingly, HbA1c
levels did attenuate the association between T2D and,
cPWV and dPWV, which may be explained by the fact that
HbA1c may also represent disease severity and duration.
Assuming that both elastin-related and collagen-related
processes contribute to increased matrix remodeling in
T2D, dPWV acts in the current study as a marker of matrix
remodeling, describing changes above and beyond carotid
stiffness. The latter is supported by our finding that adjust-
ment for cPWV does not abolish the association of T2D with
dPWV. Interestingly, the fact that dPWV is also independent
of aortic stiffness (cfPWV) further supports the notion that
dPWV reflects arterial matrix remodeling above and beyond
existing measures of arterial stiffness.
In our additional analyses, we noted that the association
of T2D with dPWV attenuated after further adjustment for
LDL cholesterol and use of lipid-modifying medication, or
BMI. This negative confounding of LDL cholesterol and the
use of lipid-modifying medication could be explained by
known positive remodeling effects of lipid-modifying
medication, which are more often used in individuals with
T2D. These positive remodeling effects, including elastin
and collagen alterations, are thought to be caused via
improving endothelial function and preventing angiotensin
II–induced vascular remodeling [41–44]. Therefore, we
cannot exclude a mediating role of LDL cholesterol and
lipid-modifying medication in the process of arterial matrix
remodeling, which may have led to overadjustment in the
investigated association with T2D [45]. The negative con-
founding of BMI in the association between T2D and dPWV
could be due to the fact that BMI can be considered as either
a confounder or ascending proxy in this association. It has
been suggested that weight loss could reduce arterial stiff-
ness and specifically arterial matrix remodeling [46,47], but
weight loss could also improve T2D and therefore arterial
stiffness and arterial matrix remodeling [48].
Recently, it has been shown that higher HR is associated
with a small increase in aortic stiffness [49]. Although T2D is
associated with a higher HR due to sympathetic overactivity
as part of autonomic neuropathy [50], the association
between T2D and carotid stiffness was not affected by
HR, whereas the association of T2D with dPWV increased.
The first could be explained by the fact that the previously
found differences were only small and may be even less
prominent in the carotid artery [40]. The latter mechanism is
TABLE 2. Associations of type 2 diabetes with carotid pulse wave velocity and systolic–diastolic difference in carotid pulse wave velocity
(as compared with normal glucose metabolism)
T2D and cPWV T2D and dPWV
Models b 95% CI b 95% CI
1. Crude 0.955 (0.654; 1.256) 0.821 (0.516; 1.126)
2. Model 1þ sex, age and MAP 0.377 (0.124; 0.629) 0.311 (0.027; 0.595)
3. Model 2þprior CVD, eGFR and smoking 0.376 (0.119; 0.632) 0.301 (0.013; 0.589)
4. Model 3þuse of RAS-inhibitor 0.322 (0.051; 0.594) 0.331 (0.026; 0.636)
5. Model 3þ dPWV/cPWVa 0.294 (0.048; 0.539) 0.173 (0.103; 0.449)
N¼746. b, regression coefficient; dPWV, systolic–diastolic difference in carotid pulse wave velocity in m/s; CI, confidence interval; cPWV, local carotid pulse wave velocity in m/s; CVD,
cardiovascular disease; eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; RAS-inhibitor, renin–angiotensin system inhibitor; T2D, type 2 diabetes.
aAs appropriate. Data of prediabetes as compared with normal glucose metabolism not shown (Table S2, http://links.lww.com/HJH/A741).
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not exactly known, but possible vasovagal imbalance in
T2D and its effect on HR [50] might complicate the interpret-
ation of positive confounding of HR on the association
between T2D and dPWV.
Previously, T2D has been associated with structural
alterations in the arterial wall in relation to wall stress
[51], as reflected by carotid artery geometry. As such, the
current study supports the disturbed arterial structure–
function relationship in T2D, by considering the dynamic
aspect of arterial distension, rather than geometry. Further-
more, although crude analyses of dPWV show a trend
among glucose metabolism status, further adjustments
for other CVD risk factors showed that prediabetes was
not associated with dPWV. Also this finding is in line with
Henry et al. [51] who found that prediabetes was not
associated with carotid arterial remodeling. It might be
that in prediabetes, maladaptation is not clearly present
yet.
Over the last decade, T2D has been associated with
increased carotid stiffness independent of other cardiovas-
cular risk factors [2,52,53]. The current study supports these
previous studies by using cPWV as a measure derived from
distensibility. Moreover, it has been shown that even before
the onset of T2D, signs of abnormal arterial stiffness are
evident in individuals with prediabetes, but this is not so
clear for specifically carotid stiffness [54]. Although crude
analyses of carotid stiffness show a trend among glucose
metabolism status, our study supports previous studies
[52,54–56] by showing that prediabetes was not associated
with carotid stiffness independent of other CVD risk factors.
A major strength of the current study is its use of deep
phenotyping that allowed us to adjust for an extensive
series of CVD risk factors in a population-based setting,
including 24-h ambulatory BP and the use of RAS-inhibi-
tors. Apparently, the association of T2D with cPWV and
dPWV is independent of possible known arterial remodel-
ing effects by these medications [29,42,57–59]. However,
our study also had some limitations. First, the cross-sec-
tional design of the study does not allow us to draw strong
causal inferences. Second, the derivation of dPWV involves
combining two measurements (tonometry and ultrasound),
in which the aggregate uncertainty of the estimate is of
consideration. Nevertheless, the measured mean dPWV
3.9 1.9 m/s ranging from 1.2 to 7.2 m/s in our 746 partici-
pants compares well with previous found values of dPWV
[6], given that our study population is older. Third, it should
be noted that increased dPWV, as applied in the current
study, does not allow differentiation between elastin degra-
dation and collagen crosslinking, whereas it reflects both.
Finally, our study population consisted of a relatively
healthy population, and possible selection bias could have
led to underestimation of our results.
Future studies utilizing dPWV should further explore the
relative contributions of elastin degradation and collagen
crosslinking, such as including plasma biomarkers for
oxidative stress, chronic low-grade inflammation and endo-
thelial dysfunction in the analyses.
In conclusion, the systolic–diastolic difference in
carotid stiffness is increased in T2D, but not prediabetes.
Importantly, the association was not abolished by carotid
stiffness, which suggests that systolic–diastolic difference
in carotid stiffness carries additional information. As such,
the systolic–diastolic difference in carotid stiffness might be
considered as a marker of arterial matrix remodeling.
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Reviewers’ Summary Evaluations
Reviewer 1
This is an excellent study in which the authors performed a
thorough phenotypic analysis of arterial stiffness in type 2
Diabetes, finding that some arterial matrix remodelling has
causative effects on it. The strength of this paper is in its
methodology. On the other hand, the small sample and the
lack of biomarkers are aspects that require further studies in
this area.
Reviewer 2
Authors investigated in a well characterized population-
based cohort the association between glucose metabolism
status and arterial properties. Individuals with T2 diabetes
had a greater carotid diameter, greater intima–media thick-
ness, a higher carotid pulse pressure and higher cPWV and
dPWV compared to individuals with normal glucose metab-
olism and prediabetes, suggesting that functional and struc-
tural properties of the arterial tree are seriously damaged in
T2 diabetes.
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